Curia

Curia

End-to-end drug development and manufacturing

Overview

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

About Curia

Simplify's Rating
Why Curia is rated
C+
Rated C on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Biotechnology

Healthcare

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Flexible, integrated services reduce sponsor handoffs and can accelerate tech transfer.[3][7]
  • Sterile fill-finish and mRNA capabilities position Curia for advanced injectable programs.[1][2]
  • Global capacity and local regulatory know-how support multinational supply redundancy.[4][6]

What critics are saying

  • Lonza, Catalent, Samsung Biologics, and WuXi Bio pressure late-stage pricing and wins.
  • A major FDA warning letter or import alert would disrupt supply and trigger customer exits.
  • Biotech funding downturns delay outsourced development work and weaken Curia's utilization.

What makes Curia unique

  • Curia spans discovery, development, regulatory, and cGMP manufacturing across modalities.[2][7]
  • It offers biologics, small molecules, sterile drug product, and high-potency capabilities.[1][2]
  • Its network covers more than 20 global locations across North America, Europe, India, and Japan.[4][13]

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$132M

Above

Industry Average

Funded Over

3 Rounds

Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Debt Funding Comparison
Coming Soon

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Carlyle Group
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb.com
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

PPI News Agency
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.

Recently Posted Jobs

Sign up to get curated job recommendations

Curia is Hiring for 75 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →